UMB Bank n.a. Purchases 123 Shares of Masimo Co. (NASDAQ:MASI)

UMB Bank n.a. raised its position in Masimo Co. (NASDAQ:MASI) by 180.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 191 shares of the medical equipment provider’s stock after acquiring an additional 123 shares during the period. UMB Bank n.a.’s holdings in Masimo were worth $32,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. HB Wealth Management LLC bought a new stake in Masimo during the 4th quarter worth about $201,000. Trust Co. of Vermont bought a new stake in Masimo during the fourth quarter worth about $33,000. Assenagon Asset Management S.A. grew its stake in Masimo by 916.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 216,051 shares of the medical equipment provider’s stock valued at $35,713,000 after purchasing an additional 194,788 shares in the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Masimo during the 4th quarter worth approximately $241,000. Finally, Nordea Investment Management AB raised its stake in shares of Masimo by 0.7% during the 4th quarter. Nordea Investment Management AB now owns 19,182 shares of the medical equipment provider’s stock worth $3,206,000 after purchasing an additional 142 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Wednesday. Piper Sandler increased their price target on Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Raymond James lifted their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. BTIG Research raised their target price on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Masimo presently has an average rating of “Moderate Buy” and an average price target of $179.67.

Masimo Stock Performance

NASDAQ MASI opened at $170.24 on Friday. The stock has a market cap of $9.11 billion, a PE ratio of 117.41 and a beta of 1.01. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $180.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm’s fifty day moving average price is $170.32 and its two-hundred day moving average price is $142.40.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 EPS. On average, equities analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.